Penta Valent Tbk PT

Penta Valent Tbk PT maintains a debt-to-equity ratio of 0.4, indicating a relatively conservative capital structure with limited leverage. The company's liquidity position is assessed as medium, with a current ratio of 1.35, suggesting it can cover short-term obligations but with limited buffer. Free cash flow of 8.85 billion IDR supports operational flexibility, though operating cash flow is negative at -18.86 billion IDR, signaling potential working capital constraints. Profitability metrics show a return on equity of 3.13% and a return on assets of 0.75%, both below the typical thresholds for pharmaceutical firms, which often exceed 10% ROE and 5% ROA. This suggests the company is underperforming relative to industry norms in terms of capital efficiency and asset utilization. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic shifts and regulatory changes, particularly in the domestic market. Looking ahead, the company's revenue is projected to grow by 4.2% in the current fiscal year and 3.8% in the next, based on historical trends and market conditions. However, the absence of significant R&D investment or new product launches may limit long-term growth potential. Risk factors include a negative net cash position after subtracting total debt, which could constrain financial flexibility. Dilution risk is assessed as low, with no recent share issuance or shelf registration activity reported. The company's capital structure remains stable, with no material adjustments applied to valuation metrics. Recent filings and transcripts indicate no major strategic shifts or regulatory challenges. The company continues to focus on cost optimization and market expansion within its core product lines.